Compare
Zymeworks Inc. vs Zevra Therapeutics, Inc. vs Siga Technologies Inc vs Standard Biotools Inc.
| Latest fiscal year | Zymeworks Inc. ZYME | Zevra Therapeutics, Inc. ZVRA | Siga Technologies Inc SIGA | Standard Biotools Inc. LAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $105.97M | $106.47M | $94.57M | $85.33M |
| Revenue growth (YoY) | +38.9% | +350.9% | -31.8% | -6.2% |
| Gross margin | n/a | n/a | 68.6% (computed) | 49.9% |
| Operating margin | -87.3% | -59.1% | 25.1% | -129.2% |
| Net margin | -76.6% | 78.2% | 24.6% | -87.8% |
| Net income | -$81.13M | $83.23M | $23.28M | -$74.90M |
| EPS (Diluted) | -$1.08 | $1.35 | $0.32 | -$0.20 |
| Operating cash flow | -$33.01M | -$1.60M | $43.47M | -$74.34M |
| Free cash flow | -$34.53M | -$2.43M | n/a | -$82.65M |
| Cash & equivalents | $41.16M | $62.41M | $154.97M | $120.86M |
| Total assets | $346.53M | $284.73M | $219.47M | $567.75M |
| Total liabilities | $78.03M | $130.07M | $20.65M | $143.46M |
| Shareholders' equity | $268.50M | $154.66M | $198.82M | $424.29M |
| Return on year-end equity | -30.2% | 53.8% | 11.7% | -17.7% |
| Shares outstanding | 74.64M | 56.85M | 71.61M | 386.38M |
Revenue, most recent five fiscal years
| Fiscal year | Zymeworks Inc. | Zevra Therapeutics, Inc. | Siga Technologies Inc | Standard Biotools Inc. |
|---|---|---|---|---|
| Latest | $105.97M Ended 2025-12-31 | $106.47M Ended 2025-12-31 | $94.57M Ended 2025-12-31 | $85.33M Ended 2025-12-31 |
| 1 year earlier | $76.30M Ended 2024-12-31 | $23.61M Ended 2024-12-31 | $138.72M Ended 2024-12-31 | $91.01M Ended 2024-12-31 |
| 2 years earlier | $76.01M Ended 2023-12-31 | $27.46M Ended 2023-12-31 | $139.92M Ended 2023-12-31 | $106.34M Ended 2023-12-31 |
| 3 years earlier | $412.48M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $110.78M Ended 2022-12-31 | $97.95M Ended 2022-12-31 |
| 4 years earlier | $26.68M Ended 2021-12-31 | $28.65M Ended 2021-12-31 | $133.67M Ended 2021-12-31 | $130.58M Ended 2021-12-31 |